Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10039350 | 0.88 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL6277688 | 0.84 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2PKMGAAIDO1 | |
| Hydrochloric Acid SCHEMBL8841049 | 0.84 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2PKMGAAIDO1 | |
| SCHEMBL4813897 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL11197684 | 0.78 | MEN1 (0.61) | ALDH1A1SMN1; SMN2PKMGAAIDO1 | |
| SCHEMBL675219 | 0.77 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2PKMGAAIDO1 | |
| SCHEMBL670769 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL26676923 | 0.76 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PKMGAAIDO1 | |
| SCHEMBL8003157 | 0.75 | CYP2C19 (0.64) | ALDH1A1SMN1; SMN2PKMGAAIDO1 | |
| SCHEMBL7355822 | 0.75 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2PKMGAAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS – BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4529473-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH (DE) | 2025-04-02 | — | — | EP | disclosed |
| WO-2023227535-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282438-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds GmbH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-2605801-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE Healthcare UK Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| CN-103096936-A | Imaging tuberculosis with pyrazinamide contrast agents | GE HEALTHCARE LTD | 2013-05-08 | — | — | CN | disclosed |
| WO-2012022812-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | CTPS1, CTPS2, MPI | ALDH1A1 1652/4885SMN1; SMN2 4820/4885PKM 1093/4885 |
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | MARS1, MARS2, BCAT1 | ALDH1A1 3187/4885SMN1; SMN2 3434/4885PKM 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.